Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Big Pharma
Oncology specialist seeks to block another bendamustine generic following trio of lawsuits in January | Firm filed complaint for patent infringement against Dr Reddy’s.   6 February 2024
Americas
Firm adds to its New York office with the appointment of ANDA expert as a partner in litigation group | Represented clients such as Gilead, Sanofi-Aventis, and Bristol-Myers Squibb in high-stakes cases.   1 February 2024
Big Pharma
PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation.   1 February 2024
Americas
Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions.   1 February 2024
Biotechnology
MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.   30 January 2024
Medtech
Biotech firm CareDx found to have infringed one of two patents-in-suit through sale of AlloSure and AlloSeq | Damages award consists of $83.6m in lost profits and $12.6m in royalties.   30 January 2024
Big Pharma
Sun Pharma’s Sezaby, used to treat infant seizures, infringes two patents says Nivagen | US firm accuses Indian rival of attempting to block patent from issuing.   25 January 2024
Big Pharma
Complaints say Slayback, Apotex and Baxter Healthcare infringed two patents through NDAs for leukaemia drug injection | Eagle patents issued in last two months expire in 2031.   23 January 2024
Americas
En banc petition concerning obviousness-type double-patenting rejected by the Court of Appeals | Decision on patent term adjustment has been closely followed by pharma companies, NYIPLA, and AIPLA.   23 January 2024
Biotechnology
The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.   18 January 2024